Literature DB >> 11745038

Congenital disorders of glycosylation and the pediatric liver.

H H Freeze1.   

Abstract

Congenital disorders of glycosylation (CDG) are caused by defects in protein N-glycosylation. These inherited disorders impact multiple organ systems, including the liver, its glycoprotein products, and the gastrointestinal system. Many patients have hypotonia, psychomotor retardation, developmental delay, and failure to thrive. Limited awareness of CDG and the diverse biological functions of glycosylation contribute to underdiagnosis of these disorders. Pediatric hepatologists and gastroenterologists are likely to encounter CDG patients early on in their workups. This review will discuss the clinical pictures, biochemistry, molecular defects, diagnosis, and, for one type, an effective treatment. The broad and diverse CDG presentations within and between the various types indicate that it should be considered in any case of unexplained developmental delay, hepatopathology, especially hepatic fibrosis and/or steatosis, protein-losing enteropathy, coagulopathy, hypoglycemia, and failure to thrive.

Entities:  

Mesh:

Year:  2001        PMID: 11745038     DOI: 10.1055/s-2001-19031

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  4 in total

Review 1.  New disorders in carbohydrate metabolism: congenital disorders of glycosylation and their impact on the endocrine system.

Authors:  Bradley S Miller; Hudson H Freeze
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.

Authors:  Ping Liu; Yi-Yang Hu; Cheng Liu; Da-Yuan Zhu; Hui-Ming Xue; Zhi-Qiang Xu; Lie-Ming Xu; Cheng-Hai Liu; Hong-Tu Gu; Zhi-Qing Zhang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation.

Authors:  Jaime Chu; Alexander Mir; Ningguo Gao; Sabrina Rosa; Christopher Monson; Vandana Sharma; Richard Steet; Hudson H Freeze; Mark A Lehrman; Kirsten C Sadler
Journal:  Dis Model Mech       Date:  2012-08-16       Impact factor: 5.758

4.  rhIGF-1 Therapy for Growth Failure and IGF-1 Deficiency in Congenital Disorder of Glycosylation Ia (PMM2 Deficiency).

Authors:  Bradley S Miller; Meghann M Duffy; O Yaw Addo; Kyriakie Sarafoglou
Journal:  J Investig Med High Impact Case Rep       Date:  2013-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.